z-logo
open-access-imgOpen Access
Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein–Barr virus is influenced by the length of the repeat and the strength of the degradation signal
Author(s) -
Nico P. Dantuma,
Stijn Heessen,
Kristina Lindsten,
Marianne Jellne,
Maria G. Masucci
Publication year - 2000
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.140217397
Subject(s) - proteolysis , ubiquitin , degradation (telecommunications) , protein degradation , fusion protein , proteasome , virus , chemistry , ubiquitin ligase , microbiology and biotechnology , biochemistry , biology , virology , recombinant dna , enzyme , gene , telecommunications , computer science
The Gly-Ala repeat (GAr) of the Epstein–Barr virus nuclear antigen-1 is a transferable element that inhibitsin cis ubiquitin/proteasome-dependent proteolysis. We have investigated this inhibitory activity by using green fluorescent protein-based reporters that have been targeted for proteolysis by N end rule or ubiquitin-fusion degradation signals, resulting in various degrees of destabilization. Degradation of the green fluorescent protein substrates was inhibited on insertion of a 25-aa GAr, but strongly destabilized reporters were protected only partially. Protection could be enhanced by increasing the length of the repeat. However, reporters containing the Ub-R and ubiquitin-fusion degradation signals were degraded even in the presence of a 239-aa GAr. In accordance, insertion of a powerful degradation signal relieved the blockade of proteasomal degradation in Epstein–Barr virus nuclear antigen-1. Our findings suggest that the turnover of natural substrates may be finely tuned by GAr-like sequences that counteract targeting signals for proteasomal destruction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here